GlassScriptPhysician profile
Kimberly M Wise
NPI 1710915178
$1,382.13
in general payments reported to CMS, 2019-2025
20 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $151 · 2021: $153 · 2022: $132 · 2023: $66.33 · 2024: $299 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $269.28 | 2022-2024 | Dextenza |
| Glaukos Corporation | $265.23 | 2025 | Idosetr |
| Alcon Vision LLC | $237.99 | 2019-2025 | Argos, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.74 | 2019-2021 | |
| Allergan, INC. | $89.57 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $54.05 | 2020-2021 | |
| Rxsight INC | $51.37 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $47.87 | 2019 | |
| Coopervision INC. | $26.32 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $24.37 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $23.29 | 2021 | |
| Abbvie INC. | $21.61 | 2022 | |
| Bausch & Lomb Americas INC. | $20.44 | 2024 | Miebo, Xiidra |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.68 | 2025 | Triesence |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.99 | 2019 | |
| Dompe US, INC. | $15.14 | 2024 | Oxervate |
| Sight Sciences, INC. | $14.31 | 2020 | |
| Optos, INC. | $13.63 | 2020 | |
| Shire North American Group INC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.